Guardant Health (NASDAQ:GH) Now Covered by Analysts at Mizuho

Equities researchers at Mizuho began coverage on shares of Guardant Health (NASDAQ:GH) in a research note issued to investors on Thursday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $55.00 price target on the stock. Mizuho’s price objective indicates a potential upside of 25.83% from the stock’s current price.

GH has been the subject of several other research reports. Scotiabank raised their target price on shares of Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Monday, February 24th. Stifel Nicolaus boosted their target price on Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Barclays began coverage on Guardant Health in a report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price target on the stock. Raymond James restated an “outperform” rating and set a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Finally, Guggenheim reiterated a “buy” rating and issued a $56.00 target price on shares of Guardant Health in a research note on Monday, February 24th. Twenty investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Guardant Health has a consensus rating of “Buy” and an average price target of $49.00.

Guardant Health Price Performance

Shares of GH stock opened at $43.71 on Thursday. The company has a market cap of $5.39 billion, a PE ratio of -12.28 and a beta of 1.45. Guardant Health has a 1 year low of $15.81 and a 1 year high of $50.89. The stock’s 50 day simple moving average is $43.57 and its two-hundred day simple moving average is $35.69.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The company had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Equities research analysts expect that Guardant Health will post -2.9 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of GH. R Squared Ltd acquired a new position in Guardant Health during the 4th quarter valued at about $26,000. SBI Securities Co. Ltd. acquired a new position in shares of Guardant Health during the fourth quarter valued at about $43,000. Kimelman & Baird LLC acquired a new position in shares of Guardant Health during the fourth quarter valued at about $58,000. NewEdge Advisors LLC boosted its stake in Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock worth $59,000 after purchasing an additional 230 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Guardant Health in the 4th quarter worth approximately $61,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.